Word mark

Trademark: 'SIGNALING PROTEOMICS' 

European Community Trademark, no. 002042802, Word mark

 

On 11. 1. 2001 the community trademark application no. 002042802 was filed for SIGNALING PROTEOMICS (Word mark) before the OAMI.The goods and services in respect of which registration of the trademark was sought are in classes 9 and 42. The current status of the trademark is application withdrawn.

Status is 'Application withdrawn'
The Community Trade Mark application has been withdrawn by the applicant for whatever reason. So right now there is no protection of this very trademark ad you can file it.

Applied11. 1. 2001
Nice classes9, 42

 
 

You can follow this trademark. You will receive an email, whenever we detect changes of the trademark filing.
This service is for free. You can unsubsribve whenever you want. More information.

 

Owner

Adress data currently not available!

Representative

KILBURN & STRODE LLP
20 Red Lion Street
WC1R 4PJ London
GB

 

If the data above is not correct, then please choose Update.

 
 

Nice classes

9  Systems and computer programs for assays in the diagnosis of diseases; systems and computer programs for chemical markers for disease states; systems and computer programs for performing diagnostics for diseases; systems and computer programs for determining targets for drugs; systems and computer programs for determining protein and peptide sequences; and scientific instruments, namely mass spectrometers, automated sample preparers for mass spectrometers, and parts and accessories for the foregoing, all for developing assays for the diagnosis of diseases, developing chemical makers for disease states, performing diagnostics for diseases, determining targets for drugs, and determining protein and peptide sequences.

42  Diagnosing diseases, developing chemical markers for disease states, determining targets for drugs, determining protein and peptide sequences, and testing candidate drug compounds for activity; scientific research for others in the fields of the diagnosis of diseases, developing chemical markers for disease states, determining targets for drugs, determining protein and peptide sequences, identifying and/or determining protein-protein, protein-ligand, protein-nucleic acid, protein-small molecule or drug interactions, testing candidate drug compounds for activity, identification of signalling effectors, pathways and/or receptors, and developing methodologies relating to the foregoing.